miR-133b as a potential regulator of a synaptic NPTX2 protein in Alzheimer's disease.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
revised:
18
07
2024
received:
07
06
2024
accepted:
24
07
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
A synaptic protein, Neuronal Pentraxin 2 (NPTX2), has emerged as a pivotal biomarker for Alzheimer's dementia (AD). We identified candidate miRNAs targeting NPTX2 and performed association and mediation analyses using multi-omics data (N = 702). Among 44 candidate miRNAs, miR-133b was significantly associated with AD and Braak positivity. Higher miR-133b expression was also associated with higher NPTX2 gene expression and better cognition. Mediation analysis showed that miR-133b partially influences AD and cognition through the NPTX2 protein. Our integrated approach suggests a potential role of miR-133b in synaptic integrity and offers new insights into AD pathogenesis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hallym University Medical Center Research Fund
Organisme : Bioamp;Medical Technology Development Program of the National Research Foundation funded by the Korean government (MSIT)
ID : RS-2023-00223501
Organisme : National Research Foundation of Korea grant funded by the Korean government (Ministry of Science and ICT)
ID : 2020R1C1C1013718
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Sweeney MD, Sagare AP, Zlokovic BV. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133‐150.
Soldan A, Oh S, Ryu T, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment. Ann Neurol. 2023;94:620‐631.
Kou X, Chen D, Chen N. The regulation of microRNAs in Alzheimer's disease. Front Neurol. 2020;11:524976.
De Jager PL, Ma Y, McCabe C, et al. A multi‐omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data. 2018;5(1):1‐13.
Johnson EC, Dammer EB, Duong DM, et al. Large‐scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26(5):769‐780.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, del Tredici K. Staging of Alzheimer disease‐associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389‐404.
de Jager PL, Ma Y, McCabe C, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834‐841.
Pyun JM, Park YH, Wang J, et al. Transcriptional risk scores in Alzheimer's disease: from pathology to cognition. Alzheimers Dement. 2024;20(1):243‐252.
Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The natural history of cognitive decline in Alzheimer's disease. Psychol Aging. 2012;27(4):1008‐1017.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15‐20.
Sticht C, De La Torre C, Parveen A, et al. miRWalk: an online resource for prediction of microRNA binding sites. PLoS One. 2018;13(10):e0206239.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodology. 1995;57(1):289‐300.
Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879‐891.
Xiao M‐F, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in Alzheimer's disease. elife. 2017;6:e23798.
Yang Q, Zhao Q, Yin Y. miR‐133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role. Exp Ther Med. 2019;18(4):2711‐2718.
Xin H, Li Y, Liu Z, et al. MiR‐133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome‐enriched extracellular particles. Stem Cells. 2013;31(12):2737‐2746.
Zhang X, Yang R, Hu B‐L, et al. Reduced circulating levels of miR‐433 and miR‐133b are potential biomarkers for Parkinson's disease. Front Cell Neurosci. 2017;11:170.